BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Mabwell and Aditum Bio Launch Kalexo Bio with $1 Billion siRNA Deal for Dyslipidemia and ASCVD

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio announced the launch of Kalexo Bio, a new company formed in conjunction with an exc...

September 18, 2025 | News

US, China and Australia Begin Phase 2 Trial of Atom Therapeutics’ ABP-745 for Acute Gout Flares

ABP-745 is an oral small molecule drug with potential applications, for other inflammatory conditions such as cardiovascular disease Atom T...

September 17, 2025 | News

China’s Biocytogen Licenses Fully Human Antibody to Tubulis for Novel ADC Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel ...

September 17, 2025 | News

Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate

Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...

September 16, 2025 | News

Rona Therapeutics Submits RN3161 to Australian HREC as INHBE-Targeting GalNAc siRNA for Obesity

Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced the successful submission of RN3161 to the Australian Human R...

September 16, 2025 | News

BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery

BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...

September 16, 2025 | News

Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer

Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...

September 15, 2025 | News

Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma

Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...

September 15, 2025 | News

Pulnovo Medical Secures Dual FDA IDE Approvals and CMS Coverage for PADN Clinical Trials in the U.S.

Pulnovo Medical, a globally recognized leader in medical devices for pulmonary hypertension (PH) and heart failure (HF), is proud to announce that its PADN...

September 15, 2025 | News

Shineco Strikes $8.7M R&D Deal and Builds Global Bridge with Singapore’s BICC

Shineco Inc., a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, announced two major strategic advances. Its subs...

September 15, 2025 | News

Cytiva’s Tonglu Site Launches First Independent R&D Product: Whatman GF10 PM2.5 Air Monitoring Paper

Cytiva, a global leader in life sciences, announced a major milestone at its Tonglu manufacturing site in China: the successful launch of its first indepen...

September 12, 2025 | News

Mednovo Doses First Patient in Phase III Trial of Targeted Radiotherapeutic for GEP-NETs

Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodot...

September 12, 2025 | News

YolTech Raises $45 Million in Series B Funding to Propel In Vivo Gene-Editing Therapies

YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $...

September 12, 2025 | News

LivingPhoenix Unveils World-First High-Resolution Imaging of Biomimetic Collagen Fibre Bundles via Cryo-EM

LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd. (hereinafter "LivingPhoenix Technology") announced that its independently ...

September 12, 2025 | News

Stay Connected